Simulations Plus (NASDAQ:SLP) Issues FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP - Get Free Report) issued an update on its FY25 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.07-1.20 for the period, compared to the consensus estimate of $1.09. The company issued revenue guidance of $90-93 million, compared to the consensus revenue estimate of $90.40 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. StockNews.com upgraded Simulations Plus from a "sell" rating to a "hold" rating in a report on Friday. Finally, KeyCorp boosted their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Simulations Plus has a consensus rating of "Moderate Buy" and a consensus price target of $49.40.

Simulations Plus Price Performance

NASDAQ SLP traded down $0.58 on Tuesday, reaching $24.25. The company had a trading volume of 275,469 shares, compared to its average volume of 175,875. Simulations Plus has a 1 year low of $23.01 and a 1 year high of $51.22. The firm has a market capitalization of $487.23 million, a PE ratio of 60.63 and a beta of 1.13. The firm has a 50-day moving average of $29.84 and a 200-day moving average of $30.22.

Simulations Plus (NASDAQ:SLP - Get Free Report) last released its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The firm had revenue of $22.43 million for the quarter, compared to analyst estimates of $21.93 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. Simulations Plus's quarterly revenue was up 22.5% on a year-over-year basis. As a group, sell-side analysts expect that Simulations Plus will post 1.09 EPS for the current fiscal year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the transaction, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 19.40% of the stock is currently owned by company insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.